Drugs Made In America Acquisition II LLC's Form 4 filing
Drugs Made In America Acquisition II Corp. (DMII) · filed Oct 1, 2025
- Accession no.
- 0001213900-25-094430
- Filed
- Oct 1, 2025
- Trade date
- Sep 26, 2025
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Drugs Made In America Acquisition II LLCCIK 0002088432 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | Ordinary shares | PPurchaseAcquired | +700,000 | –F1 | – | 15,075,000 | Direct | |
| Sep 26, 2025 | Ordinary shares | JOtherDisposed | −400,000 | –F2 | – | 14,675,000 | Direct | |
| Sep 26, 2025 | Ordinary shares | SSaleDisposed | −7,966,667 | –F3 | – | 6,708,333 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects 700,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F2
As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
Referenced by the price of 1 transaction in Table I.
- F3
As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.
Referenced by the price of 1 transaction in Table I.
- F4
The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.
Referenced by the price of 1 transaction in Table II.